The addition of apalutamide to androgen deprivation therapy is well tolerated and significantly improves survival while maintaining health-related quality of life in men with prostate cancer.
The agency granted breakthrough therapy designation to niraparib for the treatment of men with BRCA1/2-mutant positive metastatic castration-resistant prostate cancer.
Hyperbaric oxygen therapy can relieve symptoms of late radiation cystitis in patients who underwent radiotherapy of the pelvic region for prostate cancer.
Despite prolonged progression-free duration, a 25% reduction in risk of death associated with anti-androgen agent apalutamide fell short of statistical significance in patients with non-metastatic, high-risk castration-resistant prostate cancer.
The findings of a trial presented at ESMO 2019 may be a breakthrough when it comes to molecularly targeted treatment for prostate cancer.
Mushrooms reportedly have anticancer and antitumor properties, so researchers in Japan investigated to see if there was a link between mushroom intake and prostate cancer.
STUMP: Elevated PSA, family history, risk factors, and clinical findings. What is the next step in this case? Experts weigh in.
How much do you know about the incidence and screening of prostate cancer? Here's your chance to find out.
A new phase 1a/b study examined a total of 49 patients with solid tumors, including 34 with ovarian, fallopian tube, or primary peritoneal cancer, treated with a combination of the PARP 1/2 inhibitor pamiparib and the anti-PD-1 monoclonal antibody tislelizumab in several dose escalation cohorts.
Prostate cancer is the most frequent cancer found in American men, and the second leading cause of cancer death in this population. Currently, scores of reputable clinical trials are underway and recruiting patients.